Viewing stories from February, 2016
Interim Report and Half-Yearly Financial Results
Starpharma today released its interim report and financial results for the half-year ended 31 December 2015.
Financial Summary
- Reported loss of $10.0M (Dec 2014: $8.5M)
- Revenue of $3.7M (Dec 2014: $0.7M)
- R&D tax incentives of $1.8M reported in the half-year (Dec 2014: $1.6M)
- Cash position at 31 December 2015 of $54.7M (June 2015: $30.8M)
- Cash inflows of $7.2M from partners and grants, includes US$2.0M from AstraZeneca and $3.4M R&D tax incentive refund
- Proceeds from completion of $32.0M equity placement
Targeted DEP™ shows sustained superior performance
Starpharma today announced the final results of the preclinical study of its HER2-targeted DEP™ conjugate, which achieved complete tumour regression at the last study time point of 120 days post dosing.